DelMar Pharmaceuticals Inc. (DMPI)

0.97
0.01 1.11
NASDAQ : Distribution Services
Prev Close 0.98
Open 0.95
Day Low/High 0.90 / 1.00
52 Wk Low/High 0.78 / 5.20
Volume 356.95K
Avg Volume 1.06M
Exchange NASDAQ
Shares Outstanding 21.93M
Market Cap 23.24M
EPS -0.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

DelMar Pharmaceuticals Announces Issuance Of New Patent On First-in-Class DNA-targeting Agent, VAL-083

DelMar Pharmaceuticals Announces Issuance Of New Patent On First-in-Class DNA-targeting Agent, VAL-083

Newly issued patent claims provide patent protection into 2033

DelMar Pharmaceuticals Receives Approval From China's Human Genetic Resources Administration To Initiate Phase 2 Clinical Trial In Newly Diagnosed GBM

DelMar Pharmaceuticals Receives Approval From China's Human Genetic Resources Administration To Initiate Phase 2 Clinical Trial In Newly Diagnosed GBM

Biomarker-driven clinical trial will explore safety and efficacy of chemoradiation with VAL-083 as an alternative to standard-of-care temozolomide in MGMT-unmethylated GBM

DelMar Pharmaceuticals Appoints Saiid Zarrabian To The Board Of Directors And Names Dr. Erich Mohr As Chairman

DelMar Pharmaceuticals Appoints Saiid Zarrabian To The Board Of Directors And Names Dr. Erich Mohr As Chairman

Company Adopts Omnibus Equity Incentive Plan and Policy to Better Align with Shareholder Values and Facilitate Growth

These 5 Stocks Are Breaking Out

These 5 Stocks Are Breaking Out

Here's how to trade five stocks that are ready to break out and trade higher from current levels.

DelMar Pharmaceuticals Shares Decline on Thursday After Being Uplisted to Nasdaq

DelMar Pharmaceuticals Shares Decline on Thursday After Being Uplisted to Nasdaq

Biotech investors have not had much to cheer about in 2016.

Shares of DelMar End Lower on First Day of Trading

Shares of DelMar End Lower on First Day of Trading

DelMar Pharmaceuticals enjoyed a bit of good news this week after its shares were uplisted to the Nasdaq Capital Market this week.

SeeThruEquity Issues Update On DelMar Pharmaceuticals, Inc.’s VAL-083 Clinical Trial

SeeThruEquity Issues Update On DelMar Pharmaceuticals, Inc.’s VAL-083 Clinical Trial

SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued an update note on DelMar ...